Athersys (ATHX) Announces CEO Transition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Athersys Announces CEO Transition
February 16, 2021 7:00 AM ESTGil Van Bokkelen to Step Down as Chairman and CEO; B.J. Lehmann Appointed Interim CEO
Board Initiating Search for Permanent Successor; Ismail Kola appointed Chairman of the Board
Company Postpones Investor Day
CLEVELAND, Ohio--(BUSINESS WIRE)-- Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® cell therapy, today announced that Dr. Gil Van Bokkelen has stepped down as Chairman and Chief Executive Officer, effective immediately. The Athersys Board has appointed William (B.J.) Lehmann, the Companys... More



